FY2025 Earnings Estimate for ResMed Issued By Zacks Research

ResMed Inc. (NYSE:RMD) – Stock analysts at Zacks Research increased their FY2025 earnings estimates for ResMed in a research note issued to investors on Thursday, March 13th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $9.37 per share for the year, up from their prior estimate of $9.36. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q4 2025 earnings at $2.41 EPS, Q1 2026 earnings at $2.31 EPS, Q2 2026 earnings at $2.41 EPS, FY2026 earnings at $9.71 EPS and Q1 2027 earnings at $2.51 EPS.

RMD has been the topic of a number of other research reports. KeyCorp lifted their price target on shares of ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Citigroup raised shares of ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday, March 5th. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Saturday. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research note on Friday, January 31st. Finally, The Goldman Sachs Group assumed coverage on shares of ResMed in a report on Thursday, January 16th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, ResMed currently has an average rating of “Moderate Buy” and an average target price of $243.82.

ResMed Trading Up 2.2 %

Shares of ResMed stock opened at $224.48 on Monday. The firm has a market cap of $32.97 billion, a PE ratio of 26.50, a P/E/G ratio of 1.53 and a beta of 0.74. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. ResMed has a fifty-two week low of $172.19 and a fifty-two week high of $263.05. The business’s fifty day moving average is $236.30 and its two-hundred day moving average is $239.80.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%.

Hedge Funds Weigh In On ResMed

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. True Wealth Design LLC lifted its holdings in shares of ResMed by 2,200.0% during the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 110 shares during the period. Colonial Trust Co SC lifted its holdings in shares of ResMed by 6,250.0% during the fourth quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 125 shares during the period. Optiver Holding B.V. acquired a new position in ResMed in the fourth quarter valued at about $33,000. Itau Unibanco Holding S.A. increased its holdings in shares of ResMed by 1,000.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 150 shares in the last quarter. Finally, OFI Invest Asset Management acquired a new position in shares of ResMed in the 4th quarter worth approximately $39,000. 54.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total value of $484,220.00. Following the transaction, the director now owns 77,218 shares of the company’s stock, valued at $18,695,249.98. This trade represents a 2.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Kaushik Ghoshal sold 9,113 shares of ResMed stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $235.40, for a total value of $2,145,200.20. Following the completion of the transaction, the insider now owns 9,725 shares in the company, valued at $2,289,265. The trade was a 48.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,940 shares of company stock worth $9,164,385. Corporate insiders own 0.71% of the company’s stock.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.94%. The ex-dividend date of this dividend is Thursday, February 13th. ResMed’s dividend payout ratio (DPR) is presently 25.03%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.